Provider review
CoreAge Rx Review: It Sells NAD+ With Erectile-Dysfunction Copy
CoreAge Rx publishes, on its own blog, the best short checklist for spotting a peptide seller you should not buy from: watch for anyone who "can't provide lot numbers or a certificate of analysis, or ships unrefrigerated — those are signs to walk away." CoreAge provides no lot number and no certificate of analysis for any product it sells. That would be an ordinary irony were the product pages not doing something stranger. Its NAD+ injectable — a coenzyme, sold for "brain and body energy" — carries four bullet points under "Transformative Results" promising enhanced arousal, increased sexual desire, and help for "men with ED unresponsive to PDE5 inhibitors". Those four lines appear on no other page of the site, including CoreAge's actual ED product. Meanwhile its sermorelin FAQ sets out what a patient will notice in month one, month two and month three, for a molecule with no completed human trial under any name.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.coreagerx.com. A link is not a recommendation to take anything.
Provenance
What CoreAge Rx actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Sermorelin — Advertised "Starting at $99 per month". That is the 12-month prepay rate; the real one-month price is $129. The page carrying it also prints "UPfront pricing, no hidden fees" and "No Membership fees".
- NAD+ Injectable — Advertised "Starting at $93 Per month", which is the 12-month prepay rate; one month is $129.
- NAD+ Nasal Spray — Advertised "Starting at $93/mo" — again the 12-month prepay rate.
- Semaglutide — Advertised "$99/mo". That is the 12-month plan, charged as $1,188 in a single payment. One month is $190, itemised at checkout as the medication plus a $99 "Doctor Support & Monitoring" line and a $40 delivery line, both struck through to zero.
- Tirzepatide — Advertised "$149/mo", which is the 12-month plan billed as $1,788 up front. One month is $239, with any dose up to 15 mg/week included.
- Semaglutide Microdosing Therapy — Advertised "starting at $79"; one month is $169, a 114% increase — the largest gap on the site.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Products with a human trial
Out of 6 reviewed here.
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from CoreAge Rx’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
SermorelinSermorelin · Compounded (503A)No trial supports this claim
“Sermorelin is a bioidentical peptide analog of growth hormone-releasing hormone (GHRH) used in anti-aging and longevity medicine. It stimulates the pituitary gland to naturally increase the production and release of human growth hormone (HGH). Unlike synthetic HGH injections, Sermorelin works upstream to support the body's own growth hormone rhythm—making it a safer and more physiologically aligned option. […] By boosting IGF-1 and HGH, Sermorelin promotes lean muscle gain, fat loss, skin tightening, and improved sleep—restoring multiple markers of youthful function.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns NO interventional record naming sermorelin as the intervention, in any phase and at any status. Six query forms were run — intervention "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and "Geref", its withdrawn brand name — plus a free-text search of every field. The 27 studies the intervention search does return are all different molecules: tesamorelin (TH9507/Egrifta), GHRH(1-44), or unspecified "GHRH" used as a diagnostic stimulation agent. In PubMed, "sermorelin" appears in 24 titles or abstracts and ZERO carry the randomised-controlled-trial or clinical-trial publication type. The searches discriminate: run identically in the same pass, tirzepatide returned 158 registry records and 126 trial papers, tesamorelin 17 and 21, bremelanotide 10 and 11.
The mechanism is described accurately — sermorelin is a GHRH analogue, it does act on pituitary GHRH receptors, and stimulating endogenous release is genuinely different from administering HGH. Two things reach past that. "Making it a safer… option" is a comparative safety claim against synthetic HGH, and no trial has compared them; safety is the one thing that cannot be inferred from a mechanism. And "promotes lean muscle gain, fat loss, skin tightening, and improved sleep" states four outcomes as things the drug does, for a molecule with no completed human trial. ⚠ The page's FAQ goes considerably further, and is the reason this is graded unsupported rather than overstates: it tells the reader what to expect in each of the first three months, including that "by the second month, fine lines and wrinkles start to decrease and noticeable improvements in hair and nail quality are seen". A month-by-month response curve is the output of a trial. There is no trial.1,2
NAD+ InjectableNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“NAD+ (Nicotinamide Adenine Dinucleotide) Injectable is a powerful longevity and mitochondrial support therapy… Injectable NAD+ provides rapid and efficient absorption into the bloodstream for systemic and neurological rejuvenation. […] Transformative Results with NAD+ Injectable: Enhances physical arousal, sensation, and orgasmic response. Can help men with ED unresponsive to PDE5 inhibitors. Increases sexual desire in men and women. Effective for psychological and neurological libido issues.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomised trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomised-controlled-trial publication type, returns zero records. Separately, no registered trial of injected NAD+ measures erectile function, arousal or libido as an endpoint — the sexual-function claims on this page have no registry record behind them at all, for any population.
The four "Transformative Results" bullets are about sexual function, on a product page for a coenzyme sold as a "brain + body energy protocol". "Can help men with ED unresponsive to PDE5 inhibitors" is a specific clinical claim about a refractory population — the kind of statement that would need a trial in exactly that population — and no registered study of injected NAD+ measures erectile function at all. ⚠ This is not a sibling product's template bleeding through: those four lines appear on no other page of coreagerx.com, including 4Play, CoreAge's actual ED product, whose copy is entirely different and whose actives are apomorphine and three PDE5 inhibitors. The general NAD+ claims above them — mitochondrial support, DNA repair, "neurological rejuvenation" — describe real biology of the coenzyme but have no completed human trial of the injected form behind them either.3
NAD+ Nasal SprayNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“Nasal delivery bypasses the digestive system and blood-brain barrier, delivering NAD+ directly to the brain for enhanced cognitive and neuroprotective effects. […] Transformative Results with NAD+ Nasal Spray: Safe for long-term use with minimal side effects. Rapid brain delivery via intranasal route. Supports mitochondrial and metabolic function. Promotes healthy aging and DNA repair. Boosts cognitive clarity and focus.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed randomised trial of intranasal NAD+ in humans, and no registered study measures nose-to-brain delivery of NAD+ or a cognitive endpoint from it. The human literature on raising NAD+ concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route, and none of that work establishes a long-term safety profile for an intranasal preparation.
"Safe for long-term use with minimal side effects" is the most consequential sentence on the page and the least supported: it is an affirmative long-term safety claim for a compounded intranasal preparation that has never been in a registered trial, and safety over time is precisely what cannot be reasoned out from a mechanism. The delivery claim is also confused as written — it says nasal delivery "bypasses the digestive system and blood-brain barrier". Bypassing first-pass metabolism is a real property of intranasal administration; the blood-brain barrier is not something a route bypasses by default, and nose-to-brain transport for a molecule of NAD+'s size is an open research question, not an established mechanism.3
SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“GLP-1 medication is a prescription treatment prescribed for weight loss and Type 2 Diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the action of natural GLP-1, a hormone that stimulates the release of insulin and reduces the amount of glucose produced by the liver. […] GLP-1 treatment prolongs digestion, helping to maintain your feeling of fullness for a longer period.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product. No compounded semaglutide from any seller has been through a registered trial.
This is the most accurate page on the site, and notably it is the one that claims least. It describes the drug class correctly, gets the incretin mechanism right, and states gastric-emptying and satiety effects that are well established. It names no trial and quotes no weight-loss figure, so there is nothing here that outruns the evidence. The standing caveat applies — STEP 1 tested the approved finished product, not a compounded preparation — and the page does not draw that distinction.4
TirzepatideTirzepatide · Compounded (503A)Claim reaches past the trials
“GLP-1 medication is a prescription treatment prescribed for weight loss and Type 2 Diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the action of natural GLP-1, a hormone that stimulates the release of insulin and reduces the amount of glucose produced by the liver.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
The tirzepatide page's body copy is the semaglutide page's body copy, word for word — and it describes a "glucagon-like peptide-1 (GLP-1) receptor agonist". Tirzepatide is not one. It is a DUAL agonist, acting at both the GIP and the GLP-1 receptor, and the GIP half is what distinguishes it from semaglutide and is a large part of why SURMOUNT-1 produced the results it did. The page never mentions GIP. Nothing stated is a wild claim, and the described effects do occur; what is wrong is that the molecule is misdescribed as a member of a class it is not in, on the page selling it, at $90 a month more than the drug it is being confused with.5
Semaglutide Microdosing TherapySemaglutide · Compounded (503A)Claim reaches past the trials
“Semaglutide Microdosing is a longevity-focused approach designed to optimize metabolic health, insulin sensitivity, and long-term physiological function. Unlike traditional high-dose weight loss treatments, this protocol utilizes low, consistent dosing to enhance metabolic stability and promote healthy aging. […] Lower side effect profile at microdoses. Aligns with longevity and healthspan goals.”
No human trial
The molecule has phase 3 evidence; this USE does not. As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed trial of a sub-therapeutic "microdose" semaglutide regimen with longevity, healthspan or healthy-ageing endpoints. The semaglutide programme — STEP for weight, SUSTAIN for glycaemia, SELECT for cardiovascular outcomes — tested full therapeutic doses titrated to target in people with obesity or diabetes, and reported weight, HbA1c and cardiovascular events, not ageing. No registered trial supports the specific claim that a lower dose produces a better side-effect profile while retaining metabolic benefit, because no trial has tested the microdose regimen against the standard one for that trade-off.
The evidence and the claim are graded differently here, because both halves are true and they pull in opposite directions. Semaglutide genuinely improves insulin sensitivity and glycaemic control at therapeutic doses, so the individual mechanisms named are real. What has never been tested is this regimen for these purposes: a deliberately sub-therapeutic dose, taken for "healthy aging" and "healthspan", claimed to have a "lower side effect profile" while still delivering metabolic benefit. That is a dose-response claim, and dose-response is established by trials that compare doses. ⚠ Note also what the pricing does here: at an advertised $79 rising to $169 for a single month, the microdose carries the steepest prepay markup on the site — a 114% increase — for the least-evidenced use of the best-evidenced molecule.4
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere a customer would look. Every product page says "US board-certified doctors, trusted pharmacies" and "Compounded in the USA", both plural and both anonymous, and CoreAge's FAQ routes the question to a phone number and an email address rather than answering it. ⚠ The single exception is not an answer: "Manifest Pharmacy" appears once, in the Privacy Policy, as unexplained boilerplate in a list of parties data may be shared with — it is never connected to any product, and a name in a privacy policy is not a disclosed dispensing chain. What IS published clearly is the corporate structure, and it is worth reading: "All medical services… are provided exclusively by the Professional Entities (M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A.), which are independently owned and operated. DSO Fine Shrimp d/b/a CoreAgeRx provides the technology platform and administrative coordination services… does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine." So the platform disclaims medical practice, the clinical entity is a third party, and the pharmacy is unnamed — three separate parties, of which the reader can identify two.
Read on August 2026 from https://www.coreagerx.com/faq
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Nothing is published — no certificate of analysis, no lot number, no potency or sterility result, no named laboratory, no batch lookup, for any product. "Compounded in the USA" is the entire quality assertion on the product pages. That absence is worth setting beside CoreAge's own published advice, on `/tirzepatide-reviews/`: "If a seller pressures you to buy without a prescription, offers a price that's dramatically lower than market, asks you to use peer-to-peer payments, can't provide lot numbers or a certificate of analysis, or ships unrefrigerated, those are signs to walk away." CoreAge requires a prescription and does not ask for peer-to-peer payment, so two of those five do not apply to it. It provides neither a lot number nor a certificate of analysis. ⚠ Separately, every page on the site carries a Dietary Supplement Health and Education Act disclaimer in its footer — "These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease" — printed beneath pages selling compounded prescription drugs. A supplement disclaimer is the wrong instrument for a prescription platform, and read literally it disclaims the therapeutic purpose of everything CoreAge sells.
Read on August 2026 from https://www.coreagerx.com/tirzepatide-reviews/
Licensing
Licensed to dispense, and where
Coverage
Not published — no state list, inclusion or exclusion, appears anywhere on the site
Read the full licensing claim
CoreAge publishes no state coverage list at all. There is no "available in" map, no excluded-states notice and no per-product restriction anywhere in the product pages, FAQ or Terms; `statesExcluded` is empty because naming exclusions would mean inventing them, not because none exist. Prescribing is done by third-party professional entities named in the footer — M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A. — and no licence number is published for any of them, nor for any individual clinician; no prescriber is named anywhere on the site. The corporate entity is DSO Fine Shrimp LLC dba CoreAge Rx, at a Sheridan, Wyoming registered-agent address, contactable on +1 307-405-1638. ⚠ Payment is taken BEFORE clinical review: CoreAge's own checkout says it collects payment "to secure your pre-approved spot and begin the medical review process", so the card is charged before a clinician has decided whether to prescribe.
Read on August 2026 from https://www.coreagerx.com/terms
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Its semaglutide page is the most accurate thing on the site: correct drug class, correct incretin mechanism, no trial named and no weight-loss figure quoted, so nothing on it outruns the evidence.
- It publishes its corporate structure honestly and in detail — naming the three professional entities that actually prescribe, and stating plainly that the platform "does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine".
- The blog is better than the storefront. Its counterfeit-and-grey-market guidance is specific and genuinely useful, its red-flag checklist is one this site would endorse, and it is the only place in this review wave outside a single competitor's product page where a seller links to PubMed at all — two records, on two posts.
Show 4 more
- Dose is not upcharged. The one-month semaglutide price includes any dose up to 2.5 mg/week and the tirzepatide price any dose up to 15 mg/week, so titration does not silently raise the bill — which is more than several better-known sellers manage.
- Prices, once you reach the checkout, are itemised rather than bundled: the medication, a $99 support-and-monitoring line and a $40 delivery line are shown separately, with the latter two struck through to zero.
- Side-effect lists on the sermorelin and NAD+ pages are real and reasonably complete, separated into common and less-common, rather than omitted.
- No FDA warning letter — screened against the live index on the full company name and the trading name, with a positive control that fired.
- The NAD+ injectable page sells a coenzyme with erectile-dysfunction copy: "Can help men with ED unresponsive to PDE5 inhibitors", plus arousal, orgasm and libido claims. No registered trial of injected NAD+ measures any of those.
- Those four lines appear on no other page of the site — not even on 4Play, CoreAge's actual ED product — so they are orphan copy rather than a template that bled.
- The sermorelin FAQ publishes a month-by-month response timeline, including wrinkles decreasing "by the second month", for a molecule with no completed human trial under any name.
Show 11 more
- Sermorelin is called "a safer… option" than synthetic HGH. That is a comparative safety claim, and no trial has compared them.
- The tirzepatide page carries the semaglutide page's copy verbatim and describes tirzepatide as a GLP-1 receptor agonist. It is a dual GIP/GLP-1 agonist; the page never mentions GIP.
- The NAD+ nasal page claims it is "safe for long-term use with minimal side effects" — an affirmative long-term safety claim for a compounded preparation that has never been in a trial.
- It says nasal delivery "bypasses the digestive system and blood-brain barrier". Bypassing first-pass metabolism is real; bypassing the blood-brain barrier is not a property of the route.
- Every advertised price is the 12-month prepay rate, on pages printing "UPfront pricing, no hidden fees": $99 sermorelin is $129, $93 NAD+ is $129, $99 semaglutide is $190, $149 tirzepatide is $239.
- The microdose has the steepest markup of all — $79 advertised, $169 for one month, a 114% increase — for the least-evidenced use of the best-evidenced molecule.
- No pharmacy is named; the FAQ routes the question to a phone number. "Manifest Pharmacy" appears once in the Privacy Policy and is never connected to a product.
- No certificate of analysis, lot number, potency or sterility result is published — the exact two things its own blog names as signs to walk away from a seller.
- Every page carries a dietary-supplement disclaimer stating the products are "not intended to diagnose, treat, cure, or prevent any disease", beneath compounded prescription drugs.
- Payment is taken before clinical review, to "secure your pre-approved spot and begin the medical review process".
- No state coverage is published anywhere — no inclusion list, no exclusions, no per-product restrictions.
Verdict
The bottom line
CoreAge Rx knows what good looks like. It wrote the checklist — no prescription, too-cheap pricing, peer-to-peer payment, no lot number or certificate of analysis, shipped unrefrigerated — and told its readers those are signs to walk away from a seller. It then built a storefront that fails two of its own five tests, publishes no lot number and no certificate of analysis for anything, and prints a dietary-supplement disclaimer under compounded prescription drugs. The GLP-1 side is competent and fairly priced once you find the real number, though the tirzepatide page describes the wrong drug class and every advertised figure is a twelve-month prepay rate on a page promising no hidden fees. The peptide and longevity side is where a reader should slow down: sermorelin sold on a three-month response timeline that no trial has ever produced, an NAD+ nasal spray asserted to be safe long-term without a single study, and an NAD+ injectable whose "Transformative Results" are four promises about sexual function that belong to a different product and, as far as the registry is concerned, to no product at all.
Opens www.coreagerx.com. A link is not a recommendation to take anything.
CoreAge wrote the checklist
On its own blog, in a post about tirzepatide, CoreAge Rx tells readers how to spot a seller they should not buy from:
"If a seller pressures you to buy without a prescription, offers a price that's dramatically lower than market, asks you to use peer-to-peer payments, can't provide lot numbers or a certificate of analysis, or ships unrefrigerated, those are signs to walk away."
That is good advice. It is close to what this site would tell you.
CoreAge requires a prescription and does not ask for peer-to-peer payment, so two of the five plainly do not apply to it. On the other three, its own storefront is the thing being described. There is no certificate of analysis anywhere on coreagerx.com. There is no lot number. There is no potency result, no sterility result, no named laboratory and no batch lookup — for any product. The entire quality assertion on a product page is the phrase "Compounded in the USA".
None of that makes CoreAge a bad actor. It makes it a company that published the right standard and did not apply it to itself.
Full analysis — 6 more sectionsThe NAD+ page that sells erectile function · Three months of results, no trial · The tirzepatide page is the semaglutide page · What you will actually pay · Who actually fills it · What this means if you are buying
The NAD+ page that sells erectile function
CoreAge sells NAD+ two ways, injectable and nasal, both "Starting at $93". The injectable page opens accurately enough — NAD+ described as "a coenzyme present in every cell", essential for "energy metabolism, DNA repair, and healthy cellular aging". The header calls it a "Brain + body energy protocol". The bullets at the top promise "Mental clarity & sharper focus", "Healthy aging", "Energy & Recovery".
Then, under a heading reading "Transformative Results with NAD+ Injectable", the page lists these four:
"Enhances physical arousal, sensation, and orgasmic response.
Can help men with ED unresponsive to PDE5 inhibitors.
Increases sexual desire in men and women.
Effective for psychological and neurological libido issues."
Nothing above or below those four lines is about sexual function. The product is a coenzyme sold for energy and focus.
The obvious explanation is a template — some other product's block pasted in and left, which is what happened on a competitor's NAD+ page in this same roster. So that was checked. It is not a template. Those four lines appear on no other page of coreagerx.com. They are not on 4Play, which is CoreAge's actual erectile-dysfunction product: a compounded oral suspension of apomorphine with sildenafil, tadalafil and vardenafil, whose copy is entirely different and which describes its own mechanism accurately. The NAD+ lines have no source on the site at all.
Read as claims rather than as an accident, they are the strongest ones CoreAge makes anywhere. "Can help men with ED unresponsive to PDE5 inhibitors" names a specific refractory population — men for whom sildenafil and its relatives have already failed. A claim about a refractory population is a claim that would need a trial in that population. No registered study of injected NAD+ measures erectile function, arousal or libido as an endpoint, in any population. 3
Three months of results, no trial
Sermorelin is CoreAge's longevity peptide, "Starting at $99 per month", sold on the line "Builds lean muscle + supports growth hormone".
The product description is largely fair. Sermorelin really is a GHRH analogue; it really does act on receptors in the anterior pituitary; stimulating the body's own pulsatile release genuinely is different from injecting growth hormone. CoreAge explains that clearly, and better than most.
Two sentences go past it. The first: sermorelin works upstream "making it a safer and more physiologically aligned option" than synthetic HGH. Physiologically aligned is an argument from mechanism and is fine. Safer is a comparative clinical claim, and no trial has compared the two.
The second is in the FAQ, and it is the reason this page is graded the way it is:
"Typically, within the first few weeks, you should experience improved sleep, stamina and energy. By the second month, fine lines and wrinkles start to decrease and noticeable improvements in hair and nail quality are seen. Full effects such as fat loss and improved muscle mass are normally seen by month 3."
That is a response curve. Month one, month two, month three, with different outcomes appearing at each. A curve like that is the output of a trial that followed people over time and measured things.
Here is what the registries hold for sermorelin.
A ClinicalTrials.gov search returns no interventional record naming sermorelin as the intervention — none, in any phase, at any status. 1 Six query forms were run: "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", and "Geref", the brand under which it was once approved in the US and has since been withdrawn. A free-text pass across every field of every record was run too. The 27 studies the search does return are all other molecules — tesamorelin, GHRH(1-44), or an unspecified "GHRH" used as a diagnostic agent for pituitary testing.
In PubMed, "sermorelin" appears in 24 titles or abstracts and zero carry the randomised-controlled-trial or clinical-trial publication type. 2
Because a finding like that is usually a broken search, the same queries were run on three molecules that should be there. Tirzepatide: 158 registry records, 126 trial papers. Tesamorelin: 17 and 21. Bremelanotide: 10 and 11. The instrument works.
So there is no trial, and therefore no month-two result about wrinkles. This is not specific to CoreAge — sermorelin's evidence base is thin wherever it is sold, and most of this category sells it. What is specific to CoreAge is the decision to publish a timetable.
The tirzepatide page is the semaglutide page
Put CoreAge's two GLP-1 product pages side by side and the body copy is identical, word for word. Both read:
"It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists."
For semaglutide that is correct, and the page is otherwise the best-behaved on the site: right mechanism, no trial name dropped, no weight-loss percentage quoted, nothing that outruns what STEP 1 showed. 4
For tirzepatide it is wrong. Tirzepatide is a dual agonist — it acts at the GIP receptor as well as the GLP-1 receptor, and that second action is what distinguishes it from semaglutide and a large part of why SURMOUNT-1 produced the results it did. 5 CoreAge's tirzepatide page never mentions GIP. It describes the drug as a member of a class it is not in, on the page selling it, at $90 a month more than the drug it is being conflated with.
What you will actually pay
Every price on every CoreAge product page is the twelve-month prepay rate. The pages carrying those prices also print "UPfront pricing, no hidden fees" and "No Membership fees".
| Product | Advertised | One month | |---|---|---| | Sermorelin | $99 | $129 | | NAD+ (injectable or nasal) | $93 | $129 | | Semaglutide | $99 | $190 | | Tirzepatide | $149 | $239 | | Semaglutide microdose | $79 | $169 |
The $99 semaglutide figure means $1,188 charged in a single payment; $149 tirzepatide means $1,788. The intermediate plans are real and reasonable — $399 for three months of semaglutide, $714 for six — so a patient who intends to stay a year is genuinely getting the advertised rate. A patient who wants to try one month pays roughly twice what the page led with.
The microdose is the sharpest version: $79 advertised, $169 for one month, a 114% increase — the steepest markup on the site, attached to the least-evidenced use of the best-evidenced molecule. Semaglutide has phase 3 evidence for weight and glycaemia at therapeutic doses. What CoreAge sells here is a deliberately sub-therapeutic dose for "healthy aging" and "healthspan", claimed to have a "lower side effect profile" while keeping the metabolic benefit. That is a dose-response claim, and dose-response comes from trials that compare doses. None has.
There is one genuinely good thing in this pricing that should not get lost: dose is included. Any semaglutide dose up to 2.5 mg a week and any tirzepatide dose up to 15 mg a week costs the same, so titrating up does not quietly raise the bill. Several better-known sellers charge more at every step.
Who actually fills it
Nobody named. Product pages say "US board-certified doctors, trusted pharmacies" and "Compounded in the USA" — plural, anonymous. The FAQ does not answer the question; it gives a phone number and an email address. "Manifest Pharmacy" appears exactly once on the site, in the Privacy Policy, in a list of parties data may be shared with, connected to no product. A name in a privacy policy is not a disclosed dispensing chain.
What CoreAge does publish, and publishes well, is the corporate structure:
"All medical services, including clinical evaluations, treatment planning, and prescribing decisions, are provided exclusively by the Professional Entities (M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A.), which are independently owned and operated. DSO Fine Shrimp d/b/a CoreAgeRx provides the technology platform and administrative coordination services… does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine."
That is more candour about the arrangement than most of this category offers. It also means three parties stand between the reader and the vial: a platform that disclaims practising medicine, a third-party clinical group, and a pharmacy that is never named. The reader can identify two of the three.
One more thing, and it is on every page. The footer carries a dietary-supplement disclaimer: "These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease." That is the DSHEA formula, and it belongs under a supplement. CoreAge sells compounded prescription drugs, and the same footer sits beneath semaglutide, tirzepatide and sermorelin. Read literally, it disclaims the therapeutic purpose of the entire catalogue.
The site has other unedited fields — the accessibility notice invites you to email "support@DSO Fine Shrimp d/b/a CoreAgeRx.com", and the 4Play page asks "What is Smooth 4PLAY™?" with the word "Smooth" leaked in from another product. On their own those are typos. Alongside an NAD+ page selling erectile function, they suggest a storefront where copy is assembled quickly and checked rarely.
What this means if you are buying
For semaglutide, CoreAge is a reasonable option and the page is honest. Work out which plan you actually want first: one month is $190, not $99.
For tirzepatide, the same, with the caveat that the page describing it has the pharmacology wrong. One month is $239.
For sermorelin, know that you are buying a molecule with no completed human trial under any name, and that the three-month timeline on the page came from somewhere other than a study.
For NAD+, injectable or nasal, there is no completed human trial of the injected or intranasal forms, the nasal page's long-term safety assurance rests on nothing, and the injectable page's "Transformative Results" are four claims about sexual function that appear nowhere else on the site.
And before any of it, take CoreAge's own advice: ask for the lot number and the certificate of analysis. It is the company's own test, and today it does not pass it.
Questions
Frequently asked questions
What does CoreAge Rx actually cost per month?
More than the number on the page, unless you prepay for a year. Every advertised price is the 12-month rate. Sermorelin is advertised at $99 and is $129 for one month; NAD+ injectable and nasal are advertised at $93 and are $129; semaglutide is advertised at $99 and is $190; tirzepatide at $149 is $239; and the semaglutide microdose at $79 is $169, a 114% increase and the steepest gap on the site. The 12-month plans are charged in a single payment — $1,188 for semaglutide, $1,788 for tirzepatide — and there are real intermediate options, $399 for three months of semaglutide and $714 for six. The pages carrying the advertised figures also print "UPfront pricing, no hidden fees" and "No Membership fees". One genuine plus: dose is included, with any semaglutide dose up to 2.5 mg/week and any tirzepatide dose up to 15 mg/week at the same price.
Why does the NAD+ page talk about erectile dysfunction?
There is no good explanation on the site, and the obvious one has been checked and ruled out. Under "Transformative Results with NAD+ Injectable", CoreAge lists four claims about sexual function: enhanced arousal and orgasmic response, help for "men with ED unresponsive to PDE5 inhibitors", increased desire in men and women, and effectiveness for "psychological and neurological libido issues". Nothing else on the page is about sexual function — it is sold as a "brain + body energy protocol". The natural assumption is that another product's copy was pasted in, but those four lines appear on no other page of coreagerx.com, including 4Play, which is CoreAge's actual ED product and contains apomorphine plus three PDE5 inhibitors. No registered trial of injected NAD+ measures erectile function, arousal or libido as an endpoint.
Is there evidence for sermorelin?
No registered trial names it. A ClinicalTrials.gov search on 10 August 2026 returned no interventional record naming sermorelin as the intervention across six query forms — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29" and its withdrawn brand name "Geref" — plus a free-text search of every field. The 27 studies returned are other molecules, mostly tesamorelin and GHRH(1-44). In PubMed, sermorelin appears in 24 titles or abstracts and none carries the randomised-controlled-trial or clinical-trial publication type. Those searches were controlled: tirzepatide returned 158 registry records and 126 trial papers in the same pass, tesamorelin 17 and 21, bremelanotide 10 and 11. That matters for CoreAge specifically because its FAQ tells you what you will notice in month one, month two and month three — a response curve that only a trial can produce.
Does CoreAge publish a certificate of analysis?
No — and it is the company that told you to ask. On its own blog, CoreAge writes that a seller who "can't provide lot numbers or a certificate of analysis, or ships unrefrigerated" is showing "signs to walk away". Nothing on coreagerx.com publishes a certificate of analysis, a lot number, a potency or sterility result, a named laboratory or a batch lookup, for any product. The whole quality claim on a product page is "Compounded in the USA". CoreAge does require a prescription and does not ask for peer-to-peer payment, so it passes two of the five tests on its own list.
Which pharmacy does CoreAge use, and who prescribes?
The pharmacy is not named. Product pages say "trusted pharmacies" and "Compounded in the USA"; the FAQ answers the question with a phone number and an email address. "Manifest Pharmacy" appears once, in the Privacy Policy, in a list of parties data may be shared with, and is never connected to a product. The prescribing side is disclosed properly, and unusually well: CoreAge's footer states that all medical services are provided by three named third parties — M & D Integrations Inc d/b/a MD Integrations, MDI Medical Group P.C., and MD Integrations & Wellness Provider Group P.A. — and that DSO Fine Shrimp d/b/a CoreAgeRx "does not employ healthcare providers, does not participate in clinical decisions, and does not practice medicine". No individual clinician is named and no licence number is published. Payment is taken before that clinical review happens, to "secure your pre-approved spot".
Is CoreAge's tirzepatide page accurate?
Not on the pharmacology. Its body copy is the semaglutide page's copy word for word, and it describes the product as belonging to "a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists". Tirzepatide is a dual agonist, acting at both the GIP and GLP-1 receptors, and the GIP component is what distinguishes it from semaglutide and much of why SURMOUNT-1 produced the results it did. The word GIP does not appear on the page. Nothing stated is a wild claim and the effects described do occur; the molecule is simply misdescribed as a member of a class it is not in, on the page selling it, for $90 a month more than the drug it is being confused with.
Glossary
Key terms
Show definitions
- Sermorelin
- A synthetic fragment of growth hormone-releasing hormone, GHRH(1-29), which signals the pituitary to release the body's own growth hormone rather than supplying it directly. Once approved in the US as Geref; that approval has been withdrawn, and no current ClinicalTrials.gov record names sermorelin as an intervention.
- Dual GIP/GLP-1 agonist
- A drug acting at two incretin receptors rather than one. Tirzepatide is the first marketed example, and the GIP action is what separates it from semaglutide. CoreAge's tirzepatide page describes only the GLP-1 half.
- DSHEA disclaimer
- The sentence "These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease", required on dietary supplements. It is not the right disclaimer for a compounded prescription drug, and CoreAge prints it site-wide.
- Certificate of analysis
- A laboratory document reporting what a specific batch of a preparation actually contained — identity, potency, sterility, endotoxin — tied to a lot number. It is the only way a buyer can check what is in the vial. CoreAge names it as a thing to demand, and publishes none.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off CoreAge Rx's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 search: no interventional record names sermorelin as the intervention. Six query forms run — "sermorelin", "sermorelin acetate", "GHRH(1-29)", "GHRH 1-29", "growth hormone releasing hormone 1-29", "Geref" — plus a free-text pass. The 27 studies returned are tesamorelin, GHRH(1-44) or unspecified diagnostic GHRH. Positive controls in the same pass: tirzepatide 158 records, tesamorelin 17, bremelanotide 10. Run 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=sermorelin
- US National Library of Medicine (2026). PubMed search: "sermorelin"[tiab] returns 24 records; "sermorelin"[tiab] AND randomized controlled trial[pt] returns 0, as does the clinical trial publication type. Positive controls in the same pass: tirzepatide 126, tesamorelin 21, bremelanotide 11. Run 2026-08-10.. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected and intranasal NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, and no registered study measuring erectile function, arousal or libido as an endpoint for NAD+ by any route. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- CoreAge Rx (2026). "Tirzepatide Reviews" — counterfeit and grey-market guidance: "If a seller pressures you to buy without a prescription… can't provide lot numbers or a certificate of analysis, or ships unrefrigerated, those are signs to walk away." Read 2026-08-10.. coreagerx.com. https://www.coreagerx.com/tirzepatide-reviews/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.